Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study)

We investigated the effects of testosterone replacement therapy (TRT) on metabolic factors among hypogonadal men with a metabolic syndrome. From the study population of the EARTH study, which was a randomised controlled study in Japan, 65 hypogonadal patients with a metabolic syndrome, comprising the TRT group (n = 32) and controls (n = 33), were included in this study analysis. The TRT group was administered 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 12 months. Waist circumference, body mass index, body fat volume and blood pressure were measured in all patients at baseline and at 12 months. In addition, blood biochemical data, including total cholesterol, triglyceride (TG), HDL cholesterol, fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c) levels, were also evaluated. Changes in these categories from baseline to 12 months were compared between the TRT and control groups, with significant differences observed in waist circumference, body fat percentage, FPG, TG and HbA1c levels. No significant differences were observed in other parameters. TRT for 1 year was associated with improvements in some metabolic factors among Japanese men with hypogonadism and metabolic syndrome.

[1]  H. Akaza,et al.  Clinical Practice Manual for Late‐onset Hypogonadism Syndrome , 2008, International journal of urology : official journal of the Japanese Urological Association.

[2]  A. Traish,et al.  Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study , 2013, International journal of clinical practice.

[3]  O. Raitakari,et al.  Endogenous testosterone and serum lipids in middle-aged men. , 2008, Atherosclerosis.

[4]  G. Hankey,et al.  Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study. , 2009, European journal of endocrinology.

[5]  EC Tsai,et al.  Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men , 2000, International Journal of Obesity.

[6]  S. Hisasue.  Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management , 2015, International journal of urology : official journal of the Japanese Urological Association.

[7]  L. Niskanen,et al.  Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. , 2004, Diabetes care.

[8]  S. Boonen,et al.  Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. , 2013, European journal of endocrinology.

[9]  A. Lenzi,et al.  Effects of Five-Year Treatment with Testosterone Undecanoate on Metabolic and Hormonal Parameters in Ageing Men with Metabolic Syndrome , 2014, International journal of endocrinology.

[10]  S. Arver,et al.  Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men , 2015, The aging male : the official journal of the International Society for the Study of the Aging Male.

[11]  E. Metter,et al.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. , 2001, The Journal of clinical endocrinology and metabolism.

[12]  Y. Kitagawa,et al.  The correlation between highly sensitive C-reactive protein levels and erectile function among men with late-onset hypogonadism , 2016, The aging male : the official journal of the International Society for the Study of the Aging Male.

[13]  T. Takamura,et al.  Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter, randomized controlled trial in Japan (EARTH Study) , 2015, Asian journal of andrology.

[14]  G. Jackson,et al.  Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes , 2011, Diabetes Care.

[15]  J. Bancroft,et al.  The effects of exogenous testosterone on sexuality and mood of normal men. , 1992, The Journal of clinical endocrinology and metabolism.

[16]  N. Díez-Calzadilla,et al.  Cardiovascular Risk Assessment Using High-Sensitivity C-Reactive Protein in Patients with Erectile Dysfunction , 2013, Urologia Internationalis.

[17]  J. Morley,et al.  The benefits and risks of testosterone replacement therapy: a review , 2009, Therapeutics and clinical risk management.

[18]  Y. Matsuzawa.  Metabolic syndrome--definition and diagnostic criteria in Japan. , 2005, Journal of atherosclerosis and thrombosis.

[19]  M. Nishida,et al.  Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? , 2013, Urology.

[20]  T. Yanase,et al.  Late‐onset hypogonadism (LOH) and androgens: Validity of the measurement of free testosterone levels in the diagnostic criteria in Japan , 2009, International journal of urology : official journal of the Japanese Urological Association.